Skip to content

Psychopharmacology

ISSN 1432-2072, 0033-3158

637 papers in the library · 20,322 citations · publishing 1971-2026

Papers

Sort Most recent Most cited

Expectancy in placebo-controlled trials of psychedelics: if so, so what?

Psychopharmacology September 5, 2022 Matthew Butler, Luke A. Jelen, James Rucker 91 citations

Modern psychedelic research remains in an early phase, and the eventual introduction of psychedelics into clinical practice remains in doubt. In this piece, we discuss the role of blinding and expectancy in psychedelic trials, and place this in a broader historical and contemporary context of blinding in trials across the rest of healthcare. We suggest that premature and uncritical promotion...

Natural language signatures of psilocybin microdosing.

Psychopharmacology September 1, 2022 Camila Sanz, Federico Cavanna, Stephanie Müller et al. 1 citation

Serotonergic psychedelics are being studied as novel treatments for mental health disorders and as facilitators of improved well-being, mental function, and creativity. Recent studies have found mixed results concerning the effects of low doses of psychedelics ("microdosing") on these domains. However, microdosing is generally investigated using instruments designed to assess larger doses of...

Relative reinforcing effects of dibutylone, ethylone, and N-ethylpentylone: self-administration and behavioral economics analysis in rats.

Psychopharmacology September 2022 Miaojun Lai, Dan Fu, Zeming Xu et al.

Following the emergence of methylone as one of the most popular synthetic cathinones, this group of novel psychoactive substance with names ending in "-lone," such as dibutylone, ethylone, and N-ethylpentylone, appeared on the recreational drug market. The pharmacological mechanisms of dibutylone, ethylone, and N-ethylpentylone are well understood; however, to date, the reinforcing effects of...

DOI: 10.1007/s00213-022-06173-x (opens in new tab) Full text (opens in new tab) Dibutylone Ethylone Methamphetamine N-ethylpentylone +3

The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world

Psychopharmacology August 8, 2022 Rosalind Watts, Hannes Kettner, Dana Geerts et al. 159 citations

Abstract Rationale A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connectedness to self, others and the wider world have been reported by participants in clinical trials of psychedelic therapy. Such accounts have led us to a definition of the psychological construct of ‘connectedness’ as ‘a state of feeling connected to...

N-methyl-D-aspartate receptor antagonism impairs sensory gating in the auditory cortex in response to speech stimuli.

Psychopharmacology July 2022 Sara de la Salle, Joëlle Choueiry, Judy F McIntosh et al.

Deficits in early auditory sensory processing in schizophrenia have been linked to N-methyl-D-aspartate receptor (NMDAR) hypofunction, but the role of NMDARs in aberrant auditory sensory gating (SG) in this disorder is unclear. This study, conducted in 22 healthy humans, examined the acute effects of a subanesthetic dose of the NMDAR antagonist ketamine on SG as measured electrophysiologically...

DOI: 10.1007/s00213-022-06090-z (opens in new tab) Full text (opens in new tab) Auditory sensory gating N-methyl-d-aspartate receptor nmdar Schizophrenia Symptomatology

Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.

Psychopharmacology July 2022 Hildegard A Wulf, Caroline A Browne, Carlos A. Zarate et al.

Emerging evidence has implicated the endogenous opioid system in mediating ketamine's antidepressant activity in subjects with major depressive disorder. To date, mu opioid receptors have been suggested as the primary opioid receptor of interest. However, this hypothesis relies primarily on observations that the opioid antagonist naltrexone blocked the effects of ketamine in humans and rodents....

Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents.

Psychopharmacology June 1, 2022 Alaina M Jaster, Harrison J. Elder, Samuel A Marsh et al. 41 citations

Clinical studies suggest that psychedelics exert robust therapeutic benefits in a number of psychiatric conditions including substance use disorder. Preclinical studies focused on safety and efficacy of these compounds are necessary to determine the full range of psychedelics' effects. The present study explores the behavioral pharmacology of structurally distinct psychedelics in paradigms...

DOI: 10.1007/s00213-022-06092-x (opens in new tab) Full text (opens in new tab) Ergolines Hallucinogens Intracranial self-stimulation icss Phenethylamines +5

The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Psychopharmacology June 1, 2022 Genís Ona, Juliana Mendes Rocha, José Carlos Bouso et al. 41 citations

Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive properties. Despite the potential therapeutic effects, several cases of fatalities and serious adverse events related to ibogaine/noribogaine use can be found in the literature. Most studies consist in case reports or were...

DOI: 10.1007/s00213-021-05964-y (opens in new tab) Full text (opens in new tab) Adverse events Drug interactions Ibogaine risks Noribogaine safety +12

Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow.

Psychopharmacology June 1, 2022 Isabel Wießner, Marcelo Falchi, Fernanda Palhano-Fontes et al. 22 citations

Stream of thought describes the nature of the mind when it is freely roaming, a mental state that is continuous and highly dynamic as in mind-wandering or free association. Classic serotonergic psychedelics are known to profoundly impact perception, cognition and language, yet their influence on the stream of thought remains largely unexplored. To elucidate the effects of LSD on the stream of...

DOI: 10.1007/s00213-021-06006-3 (opens in new tab) Full text (opens in new tab) LSD Abstract thinking Forward flow Free association +4

The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Psychopharmacology June 1, 2022 Pablo Mallaroni, Natasha L. Mason, F R J Vinckenbosch et al. 16 citations

Novel psychedelics (NPs) are an expanding set of compounds, presenting new challenges for drug policy and opportunities for clinical research. Unlike their classical derivatives, little is known regarding their use profiles or their subjective effects. The purpose of this study was to compile usage patterns and adverse event rates for individual NPs belonging to each of three main psychedelic...

DOI: 10.1007/s00213-022-06142-4 (opens in new tab) Full text (opens in new tab) 2–4-bromo-2,5-dimethoxyphenylethanamine 2c-b 4-Acetoxy-N,N-Dimethyltryptamine 4-Aco-DMT Hallucinogen Lysergamide +4

Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.

Psychopharmacology May 1, 2022 Sam Craft, Jason Ferris, Monica J Barratt et al. 19 citations

Synthetic cannabinoid receptor agonists (SCRAs) may be used as an alternative to natural cannabis; however, they may carry a greater risk of problematic use and withdrawal. This study aimed to characterise the withdrawal symptom profile of SCRAs and compare their profile of effect with high-potency herbal cannabis. Global Drug Survey data (2015 and 2016) were used to access a clinically...

Combined effect of alcohol and cannabis on simulated driving.

Psychopharmacology May 2022 Andrew Fares, Christine M Wickens, Robert E Mann et al.

With alcohol and cannabis remaining the most commonly detected drugs in seriously and fatally injured drivers, there is a need to understand their combined effects on driving. The present study examined the effects of combinations of smoked cannabis (12.5% THC) and alcohol (target BrAC 0.08%) on simulated driving performance, subjective drug effects, cardiovascular measures, and self-reported...

Is resting-state functional connectivity altered in regular cannabis users? A systematic review of the literature.

Psychopharmacology May 2022 Hannah Thomson, Izelle Labuschagne, Lisa-Marie Greenwood et al.

Regular cannabis use has been associated with brain functional alterations within frontal, temporal, and striatal pathways assessed during various cognitive tasks. Whether such alterations are consistently reported in the absence of overt task performance needs to be elucidated to uncover the core neurobiological mechanisms of regular cannabis use. We aim to systematically review findings from...

DOI: 10.1007/s00213-021-05938-0 (opens in new tab) Full text (opens in new tab) Cannabis Brain Resting-state functional connectivity Seed-based connectivity +3

Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).

Psychopharmacology May 2022 Anahita Bassir Nia, Maria J Orejarena, Leigh Flynn et al.

Cannabis is the most common illicit drug used in the USA and its use has been rising over the past decade, while the historical gap in rates of use between men and women has been decreasing. Sex differences in the effects of cannabinoids have been reported in animal models, but human studies are sparse and inconsistent. We investigated the sex differences in the acute subjective,...

Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration.

Psychopharmacology May 2022 Ashley M Francis, Andrea Parks, Joëlle Choueiry et al.

Long-term cannabis use has been associated with the appearance of psychotic symptoms and schizophrenia-like cognitive impairments; however these studies may be confounded by concomitant use of tobacco by cannabis users. We aimed to determine if previously observed cannabis-associated deficits in sensory gating would be seen in cannabis users with no history of tobacco use, as evidenced by...

DOI: 10.1007/s00213-021-05843-6 (opens in new tab) Full text (opens in new tab) Marijuana Event-related potential Mlaep Mid-latency auditory-evoked potential +2

The CannTeen study: verbal episodic memory, spatial working memory, and response inhibition in adolescent and adult cannabis users and age-matched controls

Psychopharmacology April 29, 2022 Will Lawn, Natalia Fernandez‐Vinson, Claire Mokrysz et al. 25 citations

BACKGROUND: Preclinical and human studies suggest that adolescent cannabis use may be associated with worse cognitive outcomes than adult cannabis use. We investigated the associations between chronic cannabis use and cognitive function in adolescent and adult cannabis users and controls. We hypothesised user-status would be negatively associated with cognitive function and this relationship...

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials

Psychopharmacology April 1, 2022 Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher et al. 214 citations

RationalePsychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and effective condition masking have been raised as critical limitations to the interpretability of the research.ObjectiveIn this article, we review the many methodological...

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Psychopharmacology March 29, 2022 Manon M.j. van den Berg, Igor Magaraggia, Rudy Schreiber et al. 14 citations

Rationale: Recent trials with psychedelics in major depressive disorder and treatment-resistant depression showed remarkable improvements in depressive symptoms that can last for up to several months after even a single administration. The lack of an appropriate placebo control group-as patients are often able to discriminate the subjective effects of the drug-and an incomplete understanding of...

DOI: 10.1007/s00213-022-06106-8 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Antidepressants Brain research

Pharmacological modelling of dissociation and psychosis: an evaluation of the Clinician Administered Dissociative States Scale and Psychotomimetic States Inventory during nitrous oxide (‘laughing gas’)-induced anomalous states

Psychopharmacology March 26, 2022 Giulia Piazza, Georges Iskandar, Vanessa Hennessy et al. 14 citations

A significant obstacle to an improved understanding of pathological dissociative and psychosis-like states is the lack of readily implemented pharmacological models of these experiences. Ketamine has dissociative and psychotomimetic effects but can be difficult to use outside of medical and clinical-research facilities. Alternatively, nitrous oxide (N2O) — like ketamine, a dissociative...

Differential contributions of serotonergic and dopaminergic functional connectivity to the phenomenology of LSD

Psychopharmacology March 24, 2022 Timothy Lawn, Ottavia Dipasquale, Alexandros Vamvakas et al. 48 citations

Abstract Rationale LSD is the prototypical psychedelic. Despite a clear central role of the 5HT 2a receptor in its mechanism of action, the contributions of additional receptors for which it shows affinity and agonist activity remain unclear. Objectives We employed receptor-enriched analysis of functional connectivity by targets (REACT) to explore differences in functional connectivity (FC)...

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

Psychopharmacology March 7, 2022 Aryan Sarparast, Kelan Thomas, Benjamin Malcolm et al. 85 citations

As MDMA and psilocybin continue to move through the FDA drug development process, this systematic review offers a compilation of existing research on psychiatric drug-drug interactions with MDMA or psilocybin.

Role of 5-HT2A receptors in the effects of ayahuasca on ethanol self-administration using a two-bottle choice paradigm in male mice

Psychopharmacology March 7, 2022 Yasmim A. Serra, Thaísa Barros-Santos, Alexia Anjos-Santos et al. 28 citations

Treatment with ayahuasca during alcohol abstinence blocked the expression of alcohol self-administration in mice, and 5-HT2A receptor activation is critical for those effects to emerge. Our findings support a potential for ayahuasca and other 5-HT2A receptor agonists as adjunctive pharmacotherapies for the treatment of AUD.

DOI: 10.1007/s00213-022-06104-w (opens in new tab) Ayahuasca Self-administration Pharmacology Receptor +1

Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats

Psychopharmacology March 2, 2022 Piotr Popik, Adam S. Hogendorf, Ryszard Bugno et al. 30 citations

Time underestimation produced by (S)-ketamine could be associated with its antidepressant effects; however, it was accompanied with severe behavioral disruption. We also hypothesize that behavioral disruption produced by psychedelics objectively reflects their psychotomimetic-like actions.

MDMA and memory, addiction, and depression: dose-effect analysis

Psychopharmacology March 1, 2022 Madeline M. Pantoni, Jinah L. Kim, Kaitlin R. Van Alstyne et al.

Abstract Rationale ±3,4-Methylenedioxymethamphetamine (MDMA) is a recreational drug that shows substantial promise as a psychotherapeutic agent. Still, there is some concern regarding its behavioral toxicity, and its dose-effect relationship is poorly understood. We previously explored the role of dose in the cognitive effects of MDMA in a systematic review of existing literature and found no...

Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil.

Psychopharmacology February 18, 2022 Dimitri Daldegan-Bueno, Lucas Oliveira Maia, Carolina Marcolino Massarentti et al.

RationaleSmoking-related disease is a major problem globally. Effective smoking cessation treatments are however limited. Increasing evidence suggests that psychedelics have potential as treatments for substance use disorders and may therefore prove an option in aiding smoking cessation.ObjectivesTo establish which factors predict smoking cessation in people who reported quitting or reducing...

DOI: 10.1007/s00213-022-06063-2 (opens in new tab) Ayahuasca Psychedelic Hallucinogen Smoking cessation +9